Literature DB >> 11894997

Genetically modified immunocompetent cells in HIV infection.

G Palù1, G Li Pira, F Gennari, D Fenoglio, C Parolin, F Manca.   

Abstract

Even in the era of highly active antiretroviral therapy (HAART), gene therapy (GT) can remain a promising approach for suppressing HIV infection, especially if complemented with other forms of pharmacological and immunological intervention. A large number of vectors and targets have been studied. Here we discuss the potential of genetically treated, antigen-specific immunocompetent cells for adoptive autologous immunotherapy of HIV infection. Cellular therapies with gene-modified CD8 and CD4 lymphocytes are aimed at reconstituting the antigen-specific repertoires that may be deranged as a consequence of HIV infection. Even if complete eradication of HIV from the reservoirs cannot be achieved, reconstitution of cellular immunity specific for opportunistic pathogens and for HIV itself is a desirable option to control progression of HIV infection and AIDS pathogenesis better.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11894997     DOI: 10.1038/sj.gt.3301569

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  3 in total

1.  Preservation of clonal heterogeneity of the Pneumocystis carinii-specific CD4 T cell repertoire in HIV infected, asymptomatic individuals.

Authors:  G Li Pira; D Fenoglio; L Bottone; P Terranova; E Pontali; F Caroli; M Seri; J-C Cailliez; G Koopman; R Accolla; F del Galdo; G Abbate; R de Palma; F Manca
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

Review 2.  Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective.

Authors:  Isabelle Rivière; Michel Sadelain
Journal:  Mol Ther       Date:  2017-04-26       Impact factor: 11.454

3.  Retroviral transduction of murine primary T lymphocytes.

Authors:  James Lee; Michel Sadelain; Renier Brentjens
Journal:  Methods Mol Biol       Date:  2009
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.